Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eyegate Pharmaceuticals (EYEG), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, announced that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent application related to its lead product candidate, EGP-437.
Subscribe to our email newsletter
The patent covers a method of treating eye conditions using EyeGate’s proprietary Dexamethasone Phosphate pharmaceutical formulation delivered by ocular iontophoresis.
The patent is not limited to any particular eye condition or to a particular iontophoretic device or method, but rather is directed at the delivery of this formulation through iontophoresis to the eye of patients in need of treatment .
"This is an important addition to our patent portfolio and critical for the protection our proprietary technology as we continue rigorous and controlled testing of iontophoretic Dexamethasone Phosphate to understand its potential in our initial target indications of macular edema and non-infectious anterior uveitis," said Stephen From, President and Chief Executive Officer of EyeGate Pharma.
"By protecting the method of delivering this formulation through iontophoresis, we have substantially more control over this unique and potentially paradigm-shifting therapeutic option. We look forward to continuing the evaluation of EGP-437 in macular edema and uveitis, and to further development initiatives aimed at bringing novel, injection-sparing treatments to patients in need."
EGP-437, EyeGate Pharma’s first product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues though our proprietary innovative drug delivery system, the EyeGate(R) II Delivery System.
EGP-437 is being evaluated for treatment of non-infectious anterior uveitis and macular edema. Iontophoresis is capable of delivering substantially higher ocular drug concentrations leading to greater bioavailability and therapeutic effect, and reducing the frequency of dosing.
The EyeGate(R) II Delivery System has the potential to offer a non-invasive method of drug delivery as an alternative to the current delivery modalities used for treating ocular diseases, such as eye drops and ocular injections.
EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye.
EGP-437, the Company’s first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate(R) II Delivery System.